H igh blood pressure (BP) is a major risk factor for coronary artery disease, heart failure, stroke, renal failure, and premature mortality. 1 High BP has been estimated to cause 10.7 million deaths worldwide in 2015. 2, 3 Pharmacological interventional trials of BP-lowering therapies in patients with hypertension have demonstrated reductions in cardiovascular complications, including mortality. 4 Although several antihypertensive drug classes exist, variability in treatment response by individual patients and ethnic/racial groups, and residual risks, suggests that identification of previously unrecognized BP regulatory pathways could identify novel targets and pave the way for new treatments for cardiovascular disease prevention.
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Genetic association studies have identified >400 loci at P<5×10 −8 that influence BP. [5] [6] [7] [8] [9] [10] [11] Two recent reports independently performed discovery analyses, in sample sizes of up to ≈146 000 (CHARGE Exome BP consortium [The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium]) and ≈192 000 individuals (the European-led Exome consortia [contributory consortia, CHD Exome+, ExomeBP, and GoT2D:T2DGenes]). 8, 9 All samples were genotyped on the Illumina Exome array that was designed to interrogate rare and low frequency nonsynonymous and other putative functional variants and noncoding variants for association with biomedical traits. They each identified ≈80 promising single nucleotide variant (SNV) associations with systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), or hypertension and took them forward for replication in the reciprocal consortium 8, 9 resulting in the identification of 56 novel BP-associated loci across the 2 reports, including associations with coding and rare SNVs. A total of 100 SNVs remained of interest, but did not achieve genome-wide significance. Increasing the sample size is likely to identify additional BP-associated SNVs among these variants.
In the current report, we augmented the sample size of these studies with up to 140 886 European individuals from the UK Biobank and analyzed 77 SNVs available in the UK Biobank for association with SBP, DBP, and PP, in a total sample size of up to ≈475 000 individuals (up to ≈423 000 European [EUR]).
Materials and Methods

Samples
These analyses consisted of a meta-analysis of results from 3 independent publications, the CHARGE Exome BP consortium, 8 European-led Exome consortia (contributory consortia, CHD Exome+, ExomeBP, and GoT2D:T2DGenes), 9 and the BP analyses from the UK Biobank Cardiometabolic consortium.
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The CHARGE Exome BP consortium included 120 473 individuals of EUR descent from 15 cohorts, 21 503 individuals of African descent from 10 cohorts, and 4586 individuals of Hispanic ancestry from 2 cohorts as described previously. 8 The European-led consortia included 165 276 individuals of EUR descent from 51 cohorts and 27 487 individuals of South Asian descent from 2 cohorts. 9 The UK Biobank data included 140 886 unrelated individuals of EUR descent.
All samples from the CHARGE and European-led Exome consortia were genotyped on Exome arrays that includes ≈242 000 markers >90% of which are nonsynonymous or splice variants, with enrichment for variants with minor allele frequency (MAF)<0.05. The UK Biobank used the Affymetrix UK Biobank Axiom Array (approximately 100 000) or the Affymetrix UK BiLEVE Axiom Array (approximately 50 000) to genotype ≈800 000 SNVs with subsequent imputation based on UK10K sequencing and 1000 Genomes reference panels. SNVs with an imputation threshold INFO score of <0.10 were filtered by the Warren et al 11 9 Liu et al, 8 and Warren et al 11 examined genomic inflation factors in the contributing studies and the combined meta-analyses for each of the traits analyzed. Genomic inflation ranged between 1.04 and 1.11 in these contributing studies and therefore did not suggest that there were significant issues with population stratification. In the current analyses, 77 nonvalidated BP-associated SNVs were available for analysis across all 3 data sets.
Institutional review board approval was obtained from each participating cohort, and informed consent was obtained from all subjects. 8, 9 The UK Biobank study has approval from the North West Multi-Centre Research Ethics Committee and has Research Tissue Bank approval.
Phenotypes
Three BP traits were examined: SBP, DBP, and PP, where PP was calculated as the difference between SBP and DBP. For individuals taking antihypertensive therapies, 15 mm Hg and 10 mm Hg were added to the observed SBP and DBP, respectively, to estimate the BP that would be observed off antihypertensive therapy. 12, 13 The traits were approximately normally distributed, and no transformations of the traits were performed.
Statistical Analyses
In the CHARGE Exome BP consortium, in cohorts of unrelated individuals, single SNV association tests were implemented via linear regression in R/PLINK/SNPTEST. For family-based cohorts linear mixed-effects models in R was used to estimate kinship via R KINSHIP2 package and using the LMEKIN function, to account for familial correlations (https://cran.r-project.org/web/packages/ coxme/vignettes/lmekin.pdf; Supplemental Table 21 of Liu et  al  8 ) . The component studies of the European-led consortia (CHD Exome+, ExomeBP, and GoT2D:T2D genes) used linear regression as implemented in PLINK 14 or linear mixed models as implemented in Genome-Wide Efficient Mixed Model Association 15 or EPACTS (the Efficient Mixed-Model Association eXpedited, 16 to test variants for association with BP traits. The UK Biobank study used linear regression models as implemented in SNPTEST. 17 All studies assumed an additive allelic effects model.
All studies adjusted for age, age 2 , sex, body mass index, and additional cohort-specific covariates including (where appropriate) principal components of genetic ancestry, field centers, genotyping array, or case/control status for samples ascertained on case/control status for a non-BP trait. Both study-level QC and central QC were performed before the meta-analyses being performed. Full details are given in the reports from the component consortia. 8, 9, 11 At the consortium level, meta-analyses of cohort-level association results were performed independently within CHARGE-Exome and the European-led Exome consortia using inverse varianceweighted fixed effects meta-analysis. These meta-analyses results were combined with the UK Biobank association results using fixedeffects inverse variance-weighted meta-analysis as implemented in METAL. 18 Two meta-analyses were performed, one pan-ancestry (PA; AA, European ancestry [EUR], Hispanic, South Asian) and the other of EUR ancestry. Statistical significance was set at genomewide significance, P<5×10 −8 .
Functional Annotation
Associated variants were annotated using Human Genome Build 38 dbSNP and Entrez Gene ( The National Center for Biotechnology Information). We interrogated publically available gene expression regulatory features from the Encyclopedia of DNA Elements consortium and ROADMAP Epigenome projects using HaploReg 19 and RegulomeDB. 20 Expression quantitative trait loci (eQTLs) were assessed using data from Genotype-Tissue Expression consortium, 21 GRASP, 22 Westra et al, 23 Lappalainen et al, 24 and STARNET. 25 In addition, we used the FHS eQTL results from microarray-based gene and exon expression levels in whole blood from 5257 individuals. 26 We queried whether any of the 5 BP-associated SNVs were eQTLs for genes in the 5 BP-associated regions or whether they were in LD (r 2 >0.8) with any of the eQTLs for genes in these regions. Where putative eQTLs were identified, we verified the BP-associated SNVs were in LD (r 2 >0.8) with the top eQTL for that gene. We interrogated publicly available GWAS databases through PhenoScanner, 27 a curated database holding publicly available results from large-scale genome-wide association studies facilitating phenome scans. We report results for SNVs with P value≤5×10 −8 . Capture HiC interactions were accessed from the Capture HiC Plotter (www.CHiCP.org). Javierre et al 28 used an interaction confidence score derived using CHiCAGO software. 29 The interactions with a CHiCAGO score ≥5 in at least 1 cell type were considered as high-confidence interactions.
Results
Association results for the 77 SNVs with the 3 BP traits are shown in Table I in the Data Supplement for the PA (European, South Asian, African, and Hispanic descent) meta-analysis and in Table II in the Data Supplement for the EUR metaanalysis. Twenty-one of the 77 SNVs were associated with at least 1 BP trait with genome-wide significance, P<5×10 −8 and concordant directions of effects across the results from all contributing data sets (Table) . Sixteen SNVs (PKN2, ARH-GEF3, AFAP1, ANKDD1B, LOC105375508, ZFAT, RAB-GAP1, DBH, SYNPO2L, BDNF-AS, AGBL2, NOX4, CEP164, HOXC4, CFDP1, and COMT) were genome-wide significant in both PA and EUR samples. Two SNVs at SLC4A1AP and 7p15.2, respectively, were significant only in the PA sample, and 3 SNVs at STAB1/NT5DC2, KDM5A, and LACTB only in the EUR sample. All the significant SNVs were common (MAFs≥0.19), except the SNV at the DBH locus (PA, MAF=0.0043). While this report was in preparation, 17 of these loci were published elsewhere. 7, 10, 11 Four loci remain novel: rs9678851 (SLC4A1AP, missense), rs7437940 (AFAP1, intron), rs13303 (STAB1, missense), and rs1055144 (7p15.2, noncoding transcript; Figure IA through ID in the Data Supplement). The SLC4A1AP (rs9678851) was associated with SBP, and AFAP1 (rs7437940) and 7p15.2 (rs1055144) were associated with PP. We also observed a potentially new independent BP association (r 2 =0.001 in 1000G EUR and PA samples) at a recently published locus rs34163229 (SYN-PO2L, missense; Table; Figure IE in the Data Supplement). We used a conservative r 2 <0.1 threshold to minimize the possibility of an association because of correlation with a strongly associated established BP variant. Furthermore, conditional analyses within the ≈140 000 UK Biobank participants with comprehensive genomic coverage suggested that the association with SBP of rs34163229 was independent of the established SNV, rs4746172. Regional association plots in UK Biobank are provided in Figure IIA through IIE in the Data Supplement. Conditional analyses within the full data set was not possible given the targeted nature of the Exome array that makes claims of independence provisional. Twenty-two of the 77 SNVs had MAF≤0.01, and 1 rs3025380, a missense variant in DBH, was confirmed as a BP-associated locus.
Three of the five newly discovered BP-associated SNVs are missense variants, mapping to SLC4A1AP, STAB1, and SYNPO2L (Table and Table III (Table IV in the Data Supplement). The T allele of rs34163229, the new association at the SYNPO2L locus (G>T, Ser833Tyr, with MAF=0.15), is associated with an increase of 0.36 mm Hg in SBP per allele. This variant is in LD with another missense variant in SYNPO2L (rs3812629 r 2 =1, 1000G EUR). 30 Using Polyphen2 (http://genetics. bwh.harvard.edu/pph2/index.shtml), the SNVs rs9678851 in SLC4A1AP and rs13303 in STAB1 were predicted to be benign, whereas rs34163229 in SYNPO2L was predicted to have a possible damaging impact on the corresponding human proteins' structure and function.
We interrogated publicly available eQTL data sets through Genotype-Tissue Expression consortium, the Encyclopedia of DNA Elements consortium, RoadMap projects, PhenoScanner, 27 STARNET, 25 and Framingham Heart Study 26 to further highlight potential causal genes and mechanisms at each of the newly identified BP loci (Table III in the Data Supplement). The PP-associated SNV, rs13303, at STAB1 is correlated (r 2 >0.8 1000G EUR) with the top eQTLs for NT5DC2 in atherosclerotic lesion-free internal mammary artery, atherosclerotic aortic root, subcutaneous adipose, visceral abdominal fat, and liver tissues (all P<1×10 −11 ). 25 The rs13303 was also associated with expression levels of NT5DC2 in EBV-transformed lymphocytes, transformed fibroblasts, 25 and thyroid cells (Table III in the Data Supplement) . 21 The SBP-associated SNV at SYNPO2L (rs34163229) is correlated (r 2 =0.86 in 1000G EUR) with the top eQTL (rs2177843) for MYOZ1 in heart atrial appendage tissue (Table III in the Data  Supplement) . 21 The 5 new BP associated SNVs were not in LD with the top eQTLs for these gene regions in whole blood in the Framingham Heart Study eQTL data. We also took the opportunity to assess whether the additional 15 recently established genome-wide significant BP-associated SNVs were eQTLs in the Framingham sample. Among the genomewide significant BP SNVs, 3, rs4680 at COMT, rs12680655 at ZFAT, and rs10760260 at RABGAP1, were the top eQTL for the corresponding genes in whole blood (Table V in the Data Supplement). We also examined the 5 BP-associated SNVs in endothelial precursor cell Hi-C data (www.chicp.org) 28, 32 to explore long-range chromatin interactions. rs13303 was found to contact NISCH (score 17.34) and rs34163229 contacts USP54 (score 33.89) Finally, we assessed the association of the new BP-associated variants and their close proxies (r 2 >0.8) with cardiovascular disease risk factors, molecular metabolic traits, and clinical phenotypes using PhenoScanner, the NHGRI-EBI GWAS catalog and GRASP. 27 We observed 5 of the newly discovered BP-associated SNVs to have genome-wide significant associations with other traits, including height (7p15.2), 33 waist-to-hip ratio (STAB1 and 7p15.2), 34, 35 triglycerides (SLC4A1P), adiponectin levels (STAB1), 36 and atrial fibrillation (rs7915134 which has r 2 =0.92 in the EUR 1000G samples with rs34163229 in SYNPO2L 37 ; Table III in the Data  Supplement) .
Of the 77 analyzed SNVs, from the original Exome array analyses, 56 SNVs were not genome-wide significant in the current analysis. With ≈300 BP loci reported since the time of our analysis, we investigated whether any of the 56 SNVs that were not genome-wide significant in our meta-analysis have been reported as new BP-associated loci in any of the 3 recent publications. 7, 10, 11 Twelve SNVs in our data set were located within 1 Mb of a recently reported BP locus: CACNA1S, TSC22D2, RPL26L1, EDN1, GPRC6A, ACHE, CAV1, NOX5, PGLYRP2, NAPB, EDEM2, and KCNB1 (Tables I and II 
Discussion
We identified genome-wide significant associations with BP for 21 additional SNVs from our original Exome array analyses 8, 9 by including UK Biobank participants to augment our sample size to ≈475 000 individuals. Four of the 21 BP-related loci we identified were novel, of which 2 were missense variants and 1 was a putative new independent signal at an established locus and was a missense variant.
A missense SNV in SLC4A1AP (rs9678851) marks the PP-associated locus on chromosome 2. SLC4A1AP, encodes a solute carrier also known as kidney anion exchanger adapter protein although it is widely expressed in most GenotypeTissue Expression consortium tissues.
At the new locus on chromosome 3 (rs13303), 3 potential candidate genes are highlighted: STAB1, NT5DC2, and NISCH. STAB1 encodes stabilin1, a protein known to endocytose low-density lipoprotein cholesterol, Gram-positive bacteria and Gram-negative bacteria, and advanced glycosylation end products. 38, 39 The gene product is also referred to as CLEVER-1, a common lymphatic endothelial and vascular endothelial receptor-1, 40 which is expressed in macrophages. 41 SNX17 interacts with STAB1 and is a trafficking adaptor of STAB1 in endothelial cells. 38, 42 The rs13303 is located 500-bp downstream of NT5DC2. This additional gene is highlighted through the association of rs13303 with expression of NT5DC2 in multiple tissues (Table III in the  Data Supplement) . NT5DC2 encodes the 5′-nucleotidase domain containing 2 protein. The gene is widely expressed, with higher levels observed in the heart and coronary artery, although its function is unknown. Finally, exploration of long-range chromatin interaction identified contact of the SNV region with the genetic sequence including the gene NISCH, which encodes the nonadrenergic imidazoline-1 receptor protein localized to the cytosol and anchored to the inner layer of the plasma membrane. This protein binds to the adapter insulin receptor substrate 4 (IRS4) to mediate translocation of α5 integrin from the cell membrane to endosomes. In human cardiac tissue, this protein has been found to affect cell growth and death. 43 The PP-associated variant, rs7437940, on chromosome 4 is intronic to AFAP1 and is located in promoter histone marks New Blood Pressure-Associated Loci rsID, SNV name; gene, name of the closest gene or cytogenetic band based on Gene Entrez of NCBI; annotation, SNV annotation based on dbSNP of NCBI; chr-pos, chromosome-bp position in Human Genome build 38; trait, the blood pressure trait (diastolic blood pressure, systolic blood pressure, or pulse pressure) the variant is associated with; meta, the meta-analysis the variant is associated in, Pan-Ancestry or EURopean; A1/2, allele 1/allele 2; freq1, allele frequency for allele 1; β (SE), effect estimate, β and its SE for allele 1 from the corresponding meta-analysis; P value, P from meta-analysis; dir, direction of effect in each of the contributing consortia in the following order: EUROPEAN led Exome Consortia, UK-BIOBANK, and CHARGE-BP Consortium; HetP, P value of heterogeneity across the 3 contributing consortia; N, sample size for the trait and meta-analysis with the lowest P value; UK-BIOBANK INFO, a quality of imputation score in UK BIOBANK. For more details, see Tables I and  II in Table IV in the Data  Supplement). 44 AFAP1 encodes actin filament-associated protein 1. This protein is thought to have a role in the regulation of actin filament integrity, and formation and maintenance of the actin network. 45 At the locus on chromosome 10 (rs34163229), 2 candidate genes were highlighted (SYNPO2L and MYOZ1). SYNPO2L encodes synaptopodin like 2, which is not well characterized, but may play a role in modulating actin-based shape. The lead SNV is also associated with expression levels of MYOZ1 in heart appendage tissues. MYOZ1 encodes myozenin 1, an α-actinin and gamma filamin binding Z line protein predominantly expressed in skeletal muscle. 46 At 2 loci (SLC4A1AP and SYNPO2L), we observed >1 missense variant in high LD (r 2 >0.8). Functional follow-up of these variants are needed to disentangle the causal variants. At the SLC4A1AP locus, there are 3 misssense variants, none of which are predicted to be damaging. Two of these are in C2orf16 that is predicted to encode an uncharacterized protein. Current evidence is at the transcriptional level. Cellular assays comparing the function of SLC4A1AP with the missense variant may be developed or an animal model could be created and BP can be measured. In the first instance, a knockout model may be required, because of the predicted weak effects of the BP variants. At the SYNPO2L locus, the 2 missense variants are both in SYNPO2L, of which 1 is predicted damaging, cellular experiments testing functional effects of this variant alone or part of a haplotype maybe a good starting point.
In conclusion, we identified 4 new loci and 1 potential new SNV in a known locus, which influence BP variation and highlight specific genes and pathways that could potentially facilitate an improved understanding of BP regulation, and identify novel therapeutic targets to reduce the burden of cardiovascular disease.
